Sara A. Hurvitz, MD, FACP

Unmet Needs and Future Outlook for HER2-Targeted Therapies

December 4th 2025

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.

Exciting New Data for TNBC Therapies

December 4th 2025

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Disease State Information on TNBC

November 25th 2025

Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.

Treatment of HER2-Low and Future Therapies in Metastatic Breast Cancer

November 25th 2025

Panelists discuss how HER2-low and HER3-directed therapies are expanding precision treatment opportunities in metastatic breast cancer.

Additional Data with HER2-Targeted Agents in Metastatic Breast Cancer

November 18th 2025

Panelists discuss how newer HER2-targeted therapies show promise for CNS disease control and broader metastatic management.

Treatment Sequencing in Later Lines of Therapy in HER2+ Metastatic Breast Cancer

November 18th 2025

Panelists discuss how thoughtful sequencing of HER2-targeted agents maximizes benefit and extends survival in metastatic settings.

Rethinking Routine Use of Anthracyclines for Breast Cancer in the Modern Era

November 13th 2025

First-Line Treatment Regimens in Metastatic HER2+ Breast Cancer

November 11th 2025

Panelists discuss how evolving first-line HER2-targeted combinations are improving outcomes and redefining standards in metastatic breast cancer..

The Role of ADCs in Different Subgroups

November 11th 2025

Panelists discuss how ADCs are revolutionizing HER2-targeted therapy through precision delivery and improved tolerability across patient subgroups.

Clinical Trial Evidence for HER2-Targeted Therapies in Early Breast Cancer

November 3rd 2025

Panelists discuss how new trial data are optimizing early-stage HER2-positive breast cancer treatment through refined, evidence-based regimens.

Background Information on Targeted Therapies in Breast Cancer

November 3rd 2025

Panelists discuss how the evolution of HER2 testing and classification has redefined treatment strategies and expanded therapeutic opportunities in breast cancer.

Dr Hurvitz on Data With Gedatolisib-Based Regimens in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, shares efficacy and safety data from the VIKTORIA-1 study in endocrine-resistant HR-positive breast cancer.

Dr Hurvitz on the Rationale for Targeting PI3K and mTOR in PIK3CA Wild-Type HR+/HER2-Negative Breast Cancer

October 30th 2025

Sara A. Hurvitz, MD, FACP, explains the clinical rationale for targeting the PI3K/mTOR pathways with gedatolisib in the VIKTORIA-1 trial.

Dr Hurvitz on Sustained Benefit With Adjuvant Ribociclib Plus AI Therapy in HR+/HER2– Breast Cancer

October 19th 2025

Sara A. Hurvitz, MD, FACP, shares 5-year efficacy updates from the phase 3 NATALEE trial in HR-positive HER2-negative breast cancer.

SABCS Highlights and Future Directions in the Treatment of Breast Cancer

February 26th 2025

Panelists discuss how the continued evolution of HER2-directed therapies, particularly the expanding role of trastuzumab deruxtecan (T-DXd) across different breast cancer settings, has transformed the treatment landscape, while emphasizing the importance of appropriate patient selection, optimal sequencing strategies, and the need for education around early adoption of promising therapies in community practice settings.

Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer

February 26th 2025

Panelists discuss how emerging data from trials such as DESTINY-Breast09, which is evaluating first-line trastuzumab deruxtecan (T-DXd) with or without pertuzumab, could potentially reshape the treatment paradigm for HER2+ metastatic breast cancer (mBC) by establishing new standards for initial therapy and optimal combination approaches.

Novel and Emerging Strategies for HER2+ Breast Cancer With Brain Metastases

February 19th 2025

Panelists discuss how sequential therapy selection for patients with HER2+ breast cancer with progressive brain metastases requires careful consideration of prior treatments, patterns of progression, symptom burden, and available clinical trials, while balancing the need for both systemic disease control and CNS -specific approaches.

Insights From DESTINY-Breast12 Evaluating T-DXd in HER2+ Breast Cancer and Active and Stable Brain Metastases

February 19th 2025

Panelists discuss how the DESTINY-Breast12 trial evaluated trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer (mBC) with brain metastases, demonstrating encouraging intracranial responses and overall survival outcomes while maintaining a manageable safety profile consistent with previous T-DXd studies.

Precision in CNS Targeting: Optimizing Management of Brain Metastases in HER2+ Breast Cancer

February 12th 2025

Panelists discuss how treatment selection for patients with HER2+ breast cancer with brain metastases requires careful consideration of factors such as metastatic burden, symptomatology, and prior therapies, typically incorporating both local approaches and systemic agents with CNS activity while accounting for individual patient characteristics such as performance status, comorbidities, and preferences in developing personalized treatment plans.

Evolving Paradigms in HER2+ Advanced Breast Cancer With Brain Metastases

February 12th 2025

Panelists discuss how patients with HER2+ breast cancer frequently develop brain metastases, with recent pivotal trials such as HER2CLIMB and DESTINY-Breast03 demonstrating improved intracranial responses with newer agents such as tucatinib, and how trastuzumab deruxtecan leads to evolving standards of care (SOC) that now incorporate these targeted therapies alongside traditional local therapies.